With our data we support research in the field of inflammatory rheumatic diseases. You can find an overview of the current research projects here.
| Project number | Title | Project lead |
|---|---|---|
| 2023_25 | Is peripheral joint response to IL-17 inhibition in the spondyloarthritides site-specific? A European cohort study in psoriatic arthritis and axial spondyloarthritis | Adrian Ciurea, USZ |
| 2023_24 | Validity and reliability of the Disease Activity index for Psoriatic Arthritis (DAPSA) and DAPSA-28 in European patients with Psoriatic Arthritis (PsA) | Michael Nissen |
| 2023_17 | Comparison of DAS 28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index)/ SDAI (Simplified Disease Activity Index) scores: Which score better assesses remission or low disease activity (LDA) in patients with rheumatoid arthritis? | Rüdiger Müller |
| 2023_13 | A comparative cohort analysis of the time to treatment discontinuation and of the effectiveness of upadacitinib and tumor necrosis factor inhibitors in patients with rheumatoid arthritis: analysis of pooled data from RHUMADATA-OBRI-SCQM registries. | Denis Choquette, Axel Finckh, Claire Bombardier |
| 2023_10 | The role of the kynurenine pathway in regulating macrophage function in rheumatoid arthritis | Bojana Müller, Universitätsspital Basel |
| 2023_07 | Digital Biomarker for Monitoring and Predicting Disease Severity in the Daily Lives of Rheumatoid Arthritis Patients | Raphael Micheroli, USZ |
| 2023_05 | Early axial spondyloarthritis: Characterization, response to treatment and spinal radiographic progression in early vs. late disease | Adrian Ciurea, USZ |
| 2023_04 | Cross-country differences in bDMARD prescription behaviour: associations between socioeconomics, real world bDMARD use and disease outcomes | Delphine Courvoisier, HUG |
| 2023_03 | Therapeutic drug monitoring of JAK inhibitors as novel precision medicine instrument for acute and chronic inflammatory disorders | François Girardin |
| 2022_26 | Occurrence and pattern of MRI and radiographic involvement of sacroiliac joints and spine in a European cohort of real-life patients with psoriatic arthritis | Adrian Ciurea, USZ |
| 2022_22 | The MRI equivalent to modified New York criteria-positivity on conventional radiography of the sacroiliac joints | Adrian Ciurea, USZ |
| 2022_21 | Cohort profile: the SCQM polymyalgia rheumatica and giant cell arteritis cohort | Thomas Daikeler |
| 2022_19 | Real world data on Evusheld use and burden of disease of covid19 threat in patients with inflammatory rheumatic diseases | Kim Lauper |
| 2022_18 | The association between MRI sacroiliac joint and spine inflammation and structural lesions, physical function and spinal mobility, and other outcome measures | Adrian Ciurea, USZ |
| 2022_17 | Mechanistic modelling-based prediction of humoral vaccine responses in immuno-modulated patients with inflammatory rheumatic diseases after mRNA COVID-19 vaccination | Christoph Berger, Andrea Rubbert-Roth |
| 2022_16 | Chondrocalcinosis in Rheumatoid Arthritis: an imaging analysis on correlation with disease activity and radiographic progression of Osteoarthritis | Tobias Manigold, Thomas Hügle |
| 2022_15 | Explore the incidence of adverse events in patients treated with conventional and/or biological DMARDs | Michael Nissen |
| 2022_14 | Explore the impact of selected comorbidities and extraarticular manifestations on prescription patterns and treatment effectiveness | Michael Nissen |
| 2022_11 | Automated Dorsal Finger Fold Pattern Recognition on Real World Hand Photos as a Potential Digital Biomarker for the activity of Rheumatoid Arthritis | Thomas Hugle |
| 2022_09 | EuroSpA area E: Data mapping survey study | Michael Nissen |
| 2022_08 | Investigation of ASDAS-ESR cut-offs values for disease activity states in axial spondyloarthritis | Adrian Ciurea, USZ |
| 2022_07 | Comparison of damage progression on MRI and conventional radiography of the sacroiliac joints in axial spondyloarthritis | Raphael Micheroli, USZ |
| 2022_06 | Local vs. central readings of MRIs of the sacroiliac joints in patients with axial spondyloarthritis: investigation of agreement and the need for educational activities for local interpreters” for your information | Adrian Ciurea, USZ |
| 2022_05 | Distribution of sacroiliac joint and spine imaging findings in a large cohort of real-life patients with axial SpA | Adrian Ciurea, USZ |
| 2022_04 | Progression of sacroiliac joint and spinal structural changes in a European cohort of real-life patients with axial spondyloarthritis and psoriatic arthritis: A longitudinal analysis of magnetic resonance and X-ray images. | Adrian Ciurea, USZ |
| 2022_01 | Gender-attributable differences in patient reported outcome measures in axial spondyloarthritis. | Raphael Micheroli |
| 2021_15 | Ultrasonographic differences of synovitis grade between joint locations in rheumatoid arthritis | Raphael Micheroli |
| 2021_14 | Impact of work-related physical stress on the response to different biologics in psoriatic arthritis | Raphael Micheroli |
| 2021_13 | Impact of the Covid-19 pandemic on patient selection and treatment outcomes in spondyloarthritis patients treated with b/tsDMARDs across Europe | Kim Lauper |
| 2021_12 | Analysis of immune-tolerance in individuals with pathogenic mutations in the immunoglobulin kappa (k) light chain | Mike Recher, Diego Kyburz |
| 2021_11 | Treatment retention in SpA patients assessed with methods for interval- censored time-to-event data | Myriam Riek, Seraphina Kissling, Adrian Ciurea |
| 2021_09 | A potential role of Chlamydia infection in Rheumatoid Arthritis development | Céline Lamacchia |
| 2021_08 | Patient Clusters in Rheumatoid Arthritis Identified by Deep Learning Respond Differently to Biologic or Targeted Synthetic DMARDs | Thomas Huegle |
| 2021_07 | Impact of national treatment guidelines, schedules of reimbursement and gross domestic product on treatment outcomes in patients treated with b/tsDMARDs across European observational spondyloarthritis registries | Adrian Ciurea |
| 2021_05 | Understanding the impact of COVID-19 on the anti-apoA-1 IgG response in inflammatory rheumatism disorders | Nicolas Vuilleumier, Axel Finckh |
| 2021_04 | Understanding the heterogeneity in patient populations across EuroSpA registries - the role of national access and treatment guidelines | Michael Nissen |
| 2021_03 | Patient reported outcomes, drug adherence and clinical effectiveness of secukinumab in patients with psoriatic arthritis and axial spondylarthritis up to24 months: Results from the EuroSpA collaboration. | Burkhard Möller |
| 2021_02 | Is uveitis associated with a more severe axial disease phenotype in axial spondyloarthritis? | Adrian Ciurea |
| 2021_01 | Investigating drug-induced Chronic Kidney Disease using a pharmacogenomics approach in a multicentric framework Project | Alexander Leichtle, Burkhard Möller |
| 2020_21 | Comparison of drivers of the associations of obesity and rheumatoid arthritis disease activity and of obesity and erosive progression | Andrea Burden, Thomas Huegle |
| 2020_20 | Treatment of peripheral arthritis in the spondyloarthritides: Joint-specific response to TNF inhibitors? | Adrian Ciurea |
| 2020_19 | Enthesitis in psoriatic arthritis and axial spondyloarthritis: Pattern, risk factors, and effectiveness of tumor necrosis factor inhibitors - A EuroSpA collaboration study | Michael Nissen |
| 2020_17 | Real-world dynamics of anti-S1-binding antibodies after COVID-19 vaccination in patients with inflammatory rheumatic diseases | Andrea Rubbert-Roth, Axel Finckh |
| 2020_16 | Sex and gender differences in response to biologics among patients with rheumatoid arthritis in Switzerland. | Andrea Burden, Axel Finckh, Rafi Micheroli, Burkhard Möller |
| 2020_12 | Description and assessment of treatment gaps in rheumatoid arthritis advanced treatment | Andrea Burden, Axel Finckh, Thomas Hugle |
| 2020_11 | EuroSpA-D: Handling of missing component values in patient-reported outcomes | Stylianos Georgiadis, Myriam Riek, Swiss PI (Micheal Nissen) |
| 2020_09 | Vaccination in patients with rheumatic diseases | Kim Lauper |
| 2020_06 | Psoriasis and Axial Involvement in Spondyloarthritis | Adrian Ciurea |
| 2020_04 | Effectiveness of Abatacept and alternative biologic antirheumatic agents according to the shared epitope: The EASE study | Axel Finckh |
| 2020_03 | Risk factors of infection with SARS-CoV-2 and of a serious course of COVID-19 in inflammatory rheumatic diseases in Switzerland | Axel Finckh |
| 2020_02 | The effectiveness of a therapeutic change in RA patients with radiographic progression despite low disease activity | Ruediger Mueller, Lena Brandt |
| 2020_01 | Prediction of erosions in RA by different modifications of the standard SONAR score | Burkhard Moeller |
| 2019_24 | Prediction of remission, response and retention in patients with psoriatic arthritis and axial spondyloarthritis treated with TNF-inhibitors | Michael Nissen, Adrian Ciurea, Burkhard Moeller |
| 2019_22 | Response tolerance measures in rheumatology | Myriam Riek |
| 2019_21 | Comparative treatment efficacy in rheumatoid arthritis with and without concomitant Sjoegren syndrome (CoRASS) | Lisa Christ, Florian Kollert, Burkhard Möller |
| 2019_20 | Differences in burden of disease, treatment standard and response in patients with Psoriasis Arthritis in case of fulfilling vs not-fulfilling RCT joint count criteria | Burkhard Moeller |
| 2019_18 | SONAR SpA Validation study | Michael Nissen, Pascal Zufferey |
| 2019_16 | Predictors for loss of productivity and the effect of b/tsDMARD treatment on loss of productivity in Swiss patients with rheumatoid arthritis | Diego Kyburz |
| 2019_13 | Development of a prediction score for response to biological or targeted synthetic DMARDs in patients with inflammatory rheumatic diseases by combining clinical and -omics data | Britta Maurer, Caroline Ospelt |
| 2019_12 | Real world effectiveness of baricitinib in the Swiss RA registry | Axel Finckh |
| 2019_11 | European collaborative analysis of real-world effectiveness of JAKinhibs versus anti-TNF agents and other bDMARDs (Jak-pot) | Kim Lauper, HUG |
| 2019_10 | Gender differences in Biologicals and targeted synthetic Disease Modifying Anti-Rheumatic Drugs in Spondyloarthritis and psoriatic arthritis | Michael Nissen, Adrian Ciurea, Burkhard Moeller |
| 2019_09 | Quantifying the effects of lifestyle factors in relation to outcome from bDMARD therapy amongst patients with axSpA and PsA | Michael Nissen, Adrian Ciurea, Burkhard Moeller |
| 2019_08 | SYSCID: Discovering new biomarkers by large “multi-omics” analysis to identify individuals in pre-clinical stages of Rheumatoid Arthritis | C. Lamacchia, Axel Finckh |
| 2019_06 | The impact of body mass index on the effectiveness of in inflammatory rheumatic conditions | Andrea Burden, Axel Finckh |
| 2019_04 | Multimodal-based disease activity indices und risk of progression in rheumatoid arthritis | Giorgio Tamborrini (now Pascal Zufferey), P. Mandl |
| 2019_03 | Effectiveness of TNFi versus OMA biologica in JAK-IR patients with Rheumatoid arthritis, an observational study | Diego Kyburz |
| 2018_18 | Deep learning for the prediction of radiographic progression in rheumatoid arthritis | Thomas Huegle, Maria Kalweit |
| 2018_16 | Comparative efficacy of TNF-inhibitors (TNFi) versus other mode of action (OMA) biological DMARDs in PsA -- an observational study | Burkhard Moeller |
| 2018_09 | Bone health in PsA patients | Diana Dan, Berengere Aubry-Rozier, Daniel Aeberli |
| 2018_07 | Translating humoral immunity against apolipoprotein A1 from an emerging CV risk factor to cardiovascular risk stratification tool in IRD | Cem Gabay, Nicolas Vuilleumier |
| 2018_04 | Effect of rheumatoid arthritis treatments on the incidence of fragility /low trauma fracture | Diana Dan |
| 2018_03 | Retention and effectiveness of TNF inhibitor treatment in axial spondyloarthritis and psoriatic arthritis: an analysis from the EuroSpA collaboration | Michael Nissen, Adrian Ciurea, Cem Gabay, Burkhard Moeller |
| 2018_02 | Patient reported outcomes in patients with axial spondyloarthritis and psoriatic arthritis starting treatment with TNF inhibitors: an analysis from the EuroSpA collaboration | Michael Nissen, Adrian Ciurea, Cem Gabay, Burkhard Moeller |
| 2017_08 | COmPASS II weather sensitivity | Ulrich Walker |
| 2017_07 | COmPASS II treatment response kinetics | Ulrich Walker |
| 2017_06 | COmPASS II socioeconomic | Ulrich Walker |
| 2017_05 | COmPASS II self monitoring and feedback | Ulrich Walker |
| 2017_04 | COmPASS II correlation and fluctuation | Ulrich Walker |
| 2016_14 | The TOcilizumab Collaboration of European Registries in RA (TOCERRA) – comparative effectiveness of tocilizumab (MADACTA) | Cem Gabay, Kim Lauper |
| 2016_12 | Tenosynovitis in Rheumatoid Arthritis: Prevalence, Determinants and Outcome of Tenosynovitis detected in the SONAR-Ultrasound examination in the SCQM Cohort. | Raphael Micheroli, Giorgio Tamborrini |
| 2015_09 | Analysis of fine anti-citrullinated peptide antibody specificities, anti-carbamylated peptide antibodies and genetic characteristics in psoriatic arthritis patients | Michael Nissen |
| 2015_07 | Dosage adjustment of anti-tumor necrosis factor-alpha inhibitors in axial spondyloarthritis | Adrian Ciurea |
| 2015_03 | Impact of axSpA on work participation and the role of anti-TNF treatment | Adrian Ciurea |
| 2014_08 | The effect of body mass index on the course of disease activity in axial spondyloarthritis | Adrian Ciurea, Raphael Micheroli |
| 2014_06 | Anemia and perceived disease burden in axial spondyloarthritis | Adrian Ciurea, Anne Hofmann, Raphael Micheroli |
| 2014_05 | Regular exercise and functional outcomes in axial spondyloarthritis | Adrian Ciurea, Mauro Bachmann |
| 2013_06 | Gender differences in the SCQM axial SpA cohort | Adrian Ciurea |
| 2011_02 | Predictors for duration of remission after discontinuation of biologics therapy | Diego Kyburz |
International cooperation projects are listed for information only. Please note that the inclusion of additional staff in international projects is often not possible due to the limited size of the project group per country.